First report of cryptococcosis due to Cryptococcus gattii sensu stricto VGI in an Ivorian HIV negative patient.


Journal

Journal de mycologie medicale
ISSN: 1773-0449
Titre abrégé: J Mycol Med
Pays: France
ID NLM: 9425651

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 23 07 2020
revised: 12 01 2021
accepted: 13 01 2021
pubmed: 5 2 2021
medline: 21 10 2021
entrez: 4 2 2021
Statut: ppublish

Résumé

Cryptococcus gattii species complex is endemic to tropical and subtropical regions and is described as a causative agent of cryptococcosis in immunocompetent individuals. We describe the first case of cryptococcosis in a HIV-negative patient from Ivory Coast infected by Cryptococcus gattii sensu stricto VGI. Isolates were recovered from cerebrospinal fluid (CSF) prior to systemic antifungal treatment up to 42 days after detection of the presence of yeasts in the CSF. Eighteen isolates were recovered, genetic diversity and antifungal susceptibility analyses were performed. All the isolates belonged to the Cryptococcus gattii sensu stricto (B;VGI) and were identified as a new sequence type (ST) 553 by Multilocus Sequence Typing (MLST) analyses. Susceptibility testing showed that all the strains had a wild-type phenotype for fluconazole, amphotericin B and flucytosine. Treatment with fluconazole (1200mg/day) was initiated with success. This is the first case report of the presence of C. gattii sensu stricto VGI in a HIV-negative ivorian patient and the second report of the presence of species from the C. gattii complex species in this country.

Identifiants

pubmed: 33540367
pii: S1156-5233(21)00003-2
doi: 10.1016/j.mycmed.2021.101113
pii:
doi:

Substances chimiques

Antifungal Agents 0

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

101113

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Auteurs

V Bellet (V)

UMI 233 IRD-UM Inserm U1175 TransVIHMI, Infections Fongique et Parasitaire Laboratoire de Parasitologie et de Mycologie Médicale, UFR Pharmacie, Montpellier cedex 5, France. Electronic address: virginie.bellet@umontpellier.fr.

F K Kassi (FK)

Laboratoire de Parasitologie et de Mycologie - CeDReS (Centre de Diagnostic et de Recherche sur le SIDA et les Autres Maladies Infectieuses), UFR Pharmacie, CHU de Treichville, Université Félix Houphouët Boigny, Abidjan, Ivory Coast.

D Krasteva (D)

UMI 233 IRD-UM Inserm U1175 TransVIHMI, Infections Fongique et Parasitaire Laboratoire de Parasitologie et de Mycologie Médicale, UFR Pharmacie, Montpellier cedex 5, France.

F Roger (F)

UMI 233 IRD-UM Inserm U1175 TransVIHMI, Infections Fongique et Parasitaire Laboratoire de Parasitologie et de Mycologie Médicale, UFR Pharmacie, Montpellier cedex 5, France.

P Drakulovski (P)

UMI 233 IRD-UM Inserm U1175 TransVIHMI, Infections Fongique et Parasitaire Laboratoire de Parasitologie et de Mycologie Médicale, UFR Pharmacie, Montpellier cedex 5, France.

C Mossou (C)

Centre de Diagnostic et de Recherche sur le SIDA et les Autres Maladies Infectieuses, CHU de Treichville, Abidjan, Ivory Coast.

G A Kouakou (GA)

Centre de Diagnostic et de Recherche sur le SIDA et les Autres Maladies Infectieuses, CHU de Treichville, Abidjan, Ivory Coast.

A Doumbia (A)

Centre de Diagnostic et de Recherche sur le SIDA et les Autres Maladies Infectieuses, CHU de Treichville, Abidjan, Ivory Coast.

E Delaporte (E)

UMI 233 IRD-UM Inserm U1175 TransVIHMI, Service des Maladies Infectieuses et Tropicales, CHU Gui de Chauliac, Montpellier, France.

H Menan (H)

Laboratoire de Parasitologie et de Mycologie - CeDReS (Centre de Diagnostic et de Recherche sur le SIDA et les Autres Maladies Infectieuses), UFR Pharmacie, CHU de Treichville, Université Félix Houphouët Boigny, Abidjan, Ivory Coast.

S Bertout (S)

UMI 233 IRD-UM Inserm U1175 TransVIHMI, Infections Fongique et Parasitaire Laboratoire de Parasitologie et de Mycologie Médicale, UFR Pharmacie, Montpellier cedex 5, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH